Business
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously report
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L69JurVw8dq7IznuR4WbIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL.","length":441,"tagName":"p"},{"type":"text","content":"The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory proteins, with no variant peptides observed across multiple lots. Primary structure confirmation represents a foundational component of biosimilar development and supports AEON’s analytical similarity package for ABP-450.","length":491,"tagName":"p"},{"type":"text","content":"The AAN Annual Meeting represents the largest annual gathering of neurologists in the United States, the specialty responsible for the largest volume of therapeutic botulinum toxin injections.","length":192,"tagName":"p"},{"type":"text","content":"AAN 2026 Presentation Details:","length":30,"tagName":"p"},{"type":"text","content":"Title: Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity","length":145,"tagName":"p"},{"type":"text","content":"Format: Poster Presentation (abstract # 4146, presentation #010 in Neighborhood 7)","length":82,"tagName":"p"},{"type":"text","content":"Session: P11: General Neurology: Pharmaceuticals","length":48,"tagName":"p"},{"type":"text","content":"Presenter: Chad K. Oh, M.D...